Immuno-oncology combinations and beyond
The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals.
The end of the Humira era
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
In a bear market it’s the bad news that matters
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Clinical showdown in immuno-oncology
The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.
Device approvals drop, but the FDA has a plan
Increased headcount should allow the FDA to up the number of approvals – but not quite yet.